Literature DB >> 15161673

Differential regulation of gene expression following CD40 activation of leukemic compared to healthy B cells.

Clair S Gricks1, David Zahrieh, A Jason Zauls, Gullu Gorgun, Daniela Drandi, Katja Mauerer, Donna Neuberg, John G Gribben.   

Abstract

It is possible to differentiate malignant from healthy cells and to classify diseases based on identification of specific gene expression profiles. We hypothesized that gene expression profiling could also be used to identify differential activation of healthy and malignant cells, and as a model for this, we examined the molecular sequelae of CD40 activation of healthy and B-cell chronic lymphocytic leukemia (CLL) cells. Hierarchical clustering analysis of gene expression signatures grouped samples by CD40 activation status and further subclassified CD40-activated CLL cells from healthy B cells. Supervised analyses in healthy B cells compared to CLL cells identified differential regulation of genes governing cell cycle progression and apoptosis. CD40 signaling of CLL cells increases their susceptibility to immune recognition, but promotes survival and cell cycle arrest, making these cells potentially more resistant to chemotherapy. These results illustrate the utility of gene expression profiling to elucidate the molecular sequelae of signaling in healthy cells and altered signaling pathways in malignant cells. This type of approach should be useful to identify targets of therapy of malignant diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15161673     DOI: 10.1182/blood-2004-02-0494

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

1.  Temporal genetic program following B-cell receptor cross-linking: altered balance between proliferation and death in healthy and malignant B cells.

Authors:  Laurent D Vallat; Yuhyun Park; Cheng Li; John G Gribben
Journal:  Blood       Date:  2007-01-18       Impact factor: 22.113

2.  SAGE analysis demonstrates increased expression of TOSO contributing to Fas-mediated resistance in CLL.

Authors:  Rodrigo Proto-Siqueira; Rodrigo A Panepucci; Francisco P Careta; Abigail Lee; Andrew Clear; Kelly Morris; Carolyn Owen; Edgar G Rizzatti; Wilson A Silva; Roberto P Falcão; Marco A Zago; John G Gribben
Journal:  Blood       Date:  2008-04-23       Impact factor: 22.113

3.  The lymphatic tissue microenvironments in chronic lymphocytic leukemia: in vitro models and the significance of CD40-CD154 interactions.

Authors:  Jan A Burger; Varsha Gandhi
Journal:  Blood       Date:  2009-09-17       Impact factor: 22.113

4.  Potential pathogenetic implications of cyclooxygenase-2 overexpression in B chronic lymphoid leukemia cells.

Authors:  Paola Secchiero; Elisa Barbarotto; Arianna Gonelli; Mario Tiribelli; Carlotta Zerbinati; Claudio Celeghini; Claudio Agostinelli; Stefano A Pileri; Giorgio Zauli
Journal:  Am J Pathol       Date:  2005-12       Impact factor: 4.307

Review 5.  In Vitro and In Vivo Models of CLL-T Cell Interactions: Implications for Drug Testing.

Authors:  Eva Hoferkova; Sona Kadakova; Marek Mraz
Journal:  Cancers (Basel)       Date:  2022-06-23       Impact factor: 6.575

6.  High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia.

Authors:  Marco Herling; Kaushali A Patel; Nicole Weit; Nils Lilienthal; Michael Hallek; Michael J Keating; Dan Jones
Journal:  Blood       Date:  2009-09-21       Impact factor: 22.113

7.  Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy.

Authors:  Alan G Ramsay; Andrew J Clear; Gavin Kelly; Rewas Fatah; Janet Matthews; Finlay Macdougall; T Andrew Lister; Abigail M Lee; Maria Calaminici; John G Gribben
Journal:  Blood       Date:  2009-09-28       Impact factor: 22.113

8.  CD40L/IL-4-stimulated CLL demonstrates variation in translational regulation of DNA damage response genes including ATM.

Authors:  Larissa Lezina; Ruth V Spriggs; Daniel Beck; Carolyn Jones; Kate M Dudek; Aleksandra Bzura; George D D Jones; Graham Packham; Anne E Willis; Simon D Wagner
Journal:  Blood Adv       Date:  2018-08-14

9.  The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells.

Authors:  Elisabeth Walsby; Lawrence Pearce; Alan K Burnett; Chris Fegan; Chris Pepper
Journal:  Oncotarget       Date:  2012-05

10.  Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma.

Authors:  Egil S Blix; Jonathan M Irish; Anne Husebekk; Jan Delabie; Lise Forfang; Anne M Tierens; June H Myklebust; Arne Kolstad
Journal:  BMC Cancer       Date:  2012-10-16       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.